← Leaderboards
Anton Delwig
Siteone Therapeutics, Inc.
$2,325,019
Attributed
$3,160,017
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $888.9K · FY2015–19$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,160,017 · 3
By mechanism
R44$2,936,189 · 2
R43$223,828 · 1
Top collaborators
- John Vincent Mulcahy3 shared
Most similar at Siteone Therapeutics, Inc.
Same institution · by research overlap
- John Vincent Mulcahy$6,301,912
- Debra Odink$3,260,885
- John Cureton Hunter$6,388,430
- Sheri Denet Klas$1,802,944
- George Miljanich$601,209
Others in their field
Top investigators on “Small Business Innovation Research Grant”
- David Heimbrook · Leidos Biomedical Research, Inc.$122,677,088
- Praduman Jain · Vignet, Inc.$106,968,877
- Stephen Lev Hoffman · Sanaria, Inc.$37,771,680
- Eric Baer · Case Western Reserve University$37,136,000
- John B Buse · University Of North Carolina Chapel Hill$23,865,764
- Gary Fanger · Rise Therapeutics, Llc$23,463,293
Research focus
Small Business Innovation Research GrantPropertyPharmacologic SubstanceSafety StudyToxinIon ChannelPainPharmaceutical PreparationsPre-ClinicalProtein IsoformsToxic EffectExhibitsTransmission ProcessVoltageAcuteMedicalAnalgesicsGuanidiniumAdverse EffectsDrug KineticsDoseFundingFormulationGenetic
Grant awards (5)
GUANIDINIUM DERIVATIVES FOR THE TREATMENT OF OCULAR PAIN$888,892
R44 · FY2019 · EY · contact PI
GUANIDINIUM DERIVATIVES FOR THE TREATMENT OF OCULAR PAIN$601,128
R44 · FY2018 · EY · contact PI
Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain$829,314
R44 · FY2017 · NS
Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain$616,855
R44 · FY2016 · NS
Guanidinium Derivatives for the Treatment of Ocular Pain$223,828
R43 · FY2015 · EY · contact PI